Table 2.
Type-specific HPV prevalence among US adult women by HPV vaccination status
| Prevalence (95% CI)a |
Adjusted Prevalence Ratio (95% CI) Vaccinated vs. Unvaccinated |
||||
|---|---|---|---|---|---|
| Vaccinated (n = 177) | Unvaccinated (n = 701) | Prevalence Ratio (95% CI) | Model 1b | Model 2c | |
| Any HPV Type | 63.3 (55.2–71.4) | 54.9 (50.0–59.8) | 1.15 (0.99–1.34) | 1.15 (0.98–1.34) | 1.11 (0.96–1.29) |
| Low-Risk Type | 39.1 (31.1–47.2) | 39.3 (33.7–45.0) | 0.99 (0.78–1.27) | 0.97 (0.76–1.24) | 0.93 (0.74–1.18) |
| High-Risk Type | 53.4 (43.8–63.0) | 44.4 (39.6–49.1) | 1.20 (0.99–1.46) | 1.15 (0.95–1.40) | 1.11 (0.93–1.33) |
| HPV 6, 11, 16 or 18 | 7.4 (2.1–12.7) | 17.1 (13.9–20.3) | 0.43 (0.21–0.88) | 0.41 (0.21–0.84) | 0.41 (0.20–0.82) |
| HPV 6 or 11 | 0.3 (0.0–0.8) | 4.4 (2.8–6.0) | 0.07 (0.01–0.45) | 0.07 (0.01–0.55) | 0.07 (0.01–0.54) |
| HPV 16 or 18 | 7.1 (1.7–12.5) | 13.9 (10.9–17.0) | 0.51 (0.24–1.10) | 0.47 (0.22–1.00) | 0.46 (0.22–0.98) |
| Nonvaccine Type | 62.4 (54.3–70.5) | 52.8 (47.8–57.8) | 1.18 (1.02–1.37) | 1.17 (1.00–1.37) | 1.14 (0.99–1.31) |
| Nonvaccine Low-Risk Type | 38.8 (30.8–46.9) | 37.5 (31.8–43.2) | 1.04 (0.80–1.34) | 1.00 (0.77–1.30) | 0.96 (0.75–1.23) |
| Nonvaccine High-Risk Type | 52.1 (42.5–61.8) | 40.4 (35.9–44.9) | 1.29 (1.06–1.57) | 1.23 (1.02–1.50) | 1.19 (0.99–1.43) |
CI:
confidence interval.
a
Prevalence was weighted using sample weights.
b
Model 1 was adjusted for age, race/ethnicity, education, income, smoking status, and marital status.
c
Model 2 was adjusted for variables in Model 1 plus sexually transmitted diseases and number of lifetime sexual partners, and number of sexual partners in the past 12 months.